SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2021

The following table summarizes our contract assets:


as of December 31 (in millions)	2021		2020
Contract manufacturing services	$	50	$	47
Software sales	45		40
Bundled equipment and consumable medical products contracts	100		47
Contract assets	$	195	$	134

The following table summarizes the classification of contract assets and contract liabilities as reported in the consolidated balance sheet:


as of December 31 (in millions)	2021		2020
Prepaid expenses and other current assets	$	84	$	70
Other non-current assets	111		64
Contract assets	$	195	$	134

Accrued expenses and other current liabilities	$	162	$	32
Other non-current liabilities	84		34
Contract liabilities	$	246	$	66

Disaggregation of Revenue

The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:


	2021						2020						2019
years ended December 31 (in millions)	U.S.		International		Total		U.S.		International		Total		U.S.		International		Total
Renal Care1	$	890	$	3,010	$	3,900	$	848	$	2,909	$	3,757	$	791	$	2,848	$	3,639
Medication Delivery2	1,859		1,021		2,880		1,738		953		2,691		1,762		977		2,739
Pharmaceuticals3	753		1,538		2,291		849		1,249		2,098		904		1,215		2,119
Clinical Nutrition4	343		621		964		330		580		910		308		552		860
Advanced Surgery5	545		432		977		516		370		886		533		342		875
Acute Therapies6	287		495		782		286		454		740		184		351		535
BioPharma Solutions7	273		396		669		234		252		486		257		212		469
Patient Support Systems8	86		29		115		—		—		—		—		—		—
Front Line Care9	51		19		70		—		—		—		—		—		—
Surgical Solutions10	12		15		27		—		—		—		—		—		—
Other11	81		28		109		77		28		105		87		39		126
Total Baxter	$	5,180	$	7,604	$	12,784	$	4,878	$	6,795	$	11,673	$	4,826	$	6,536	$	11,362

1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices.

3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7 BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.

8 Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies.

9 Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.

10 Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.

11 Other includes sales of miscellaneous product and service offerings.

Schedule of New Accounting Standards

The following table summarizes the allowance for doubtful accounts.


years ended December 31 (in millions)	2021		2020
Balance at beginning of period	$	125	$	112
Acquisition	13		—
Adoption of new accounting standard	—		4
Charged to costs and expenses	(2)		11
Write-offs	(5)		(4)
Currency translation adjustments	(9)		2

Balance at end of period	$	122	$	125